4Q EARNINGS: Pfizer investors look ahead to new cancer drug, business split
This article was originally published in Scrip
Executive Summary
Two questions dominated Pfizer’s fourth-quarter conference call: How quickly is the company going to shed its off-patent drugs and what’s the confidence level for an experimental cancer treatment, palbociclib?